Latest News

MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights
MEI Pharma Announces Closing of Public Offering of Common Stock
MEI Pharma Announces Pricing of Public Offering of Common Stock